Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

New Options to Treat Alcohol Use Disorder

YourUpdateTV

Nearly 15 million Americans have alcohol use disorder and 75 million engaged in binge drinking or heavy alcohol use in the month before a survey conducted by the National Institute of Alcohol Abuse and Alcoholism. This problem has not been solved…yet. Hope for a solution is one of the big stories coming out of the Wonderland Conference, the largest psychedelic business event, ever. YourUpdateTV spoke with Awakn Life Sciences CEO, Anthony Tennyson who discussed the problem. “Alcohol addiction is a chronic disease effecting many millions of Americans each year. The success rates for treatments are typically quite low though. Three out of four people are back drinking alcohol within 12 months of seeking treatment. There is, however, a new hope. Psychedelic assisted therapy has been proven to be more effective at treating alcohol addiction than any other currently available treatment.” Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, recently announced that the ‘Ketamine in the Reduction of Alcoholic Relapse’ (KARE) psychotherapy intervention study, which was the first controlled study in the world to investigate ketamine-assisted psychotherapy, will be published in the American Journal of Psychiatry later this year. Professor David Nutt, former Clinical Director of the US National Institute of Alcohol Abuse and Alcoholism and currently Clinical Director at Awakn commented. The approach we’re taking is to use new medicines to disrupt the brains processes of addiction to allow people to escape from the repetitive cravings and which tie them to the alcohol and and also with therapy to help them plot a new path in their lives. About Awakn Life Sciences Corp.: Awakn Life Sciences is a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will deliver this evidence backed psychedelic therapies in clinics in the UK and Europe and through licensing partnerships globally. About YourUpdateTV: YourUpdateTV is a social media video portal for organizations to share their content. It includes separate channels for Health and Wellness, Lifestyle, Media and Entertainment, Money and Finance, Social Responsibility, Sports and Technology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 15, 2021 07:11 PM Eastern Standard Time

Video

POCONO ORGANICS INTRODUCES NEW CBD GOURMET GUM DROP LINE

Pocono Organics

Pocono Organics’ CBD product line continues to grow as the woman-owned company introduced two new flavorful gourmet attractions, Lemon Chamomile and Vanilla Lavender CBD Gum Drops today. From hemp growing in the nutrient rich fields; transformed into new life as gourmet gum drops formulated by their scientists and Chopped Champion Chef, the pair puts Pocono Organics on the map with the number one form of CBD consumption. “Growing the first and only Regenerative Organic Certified (ROC) hemp in the world and being the largest ROC farm in the U.S.; we tend to set the bar kind of high for our CBD team to excel in creating a premium, wellness product line dedicated to providing convenience and taste-appeal,” smiles Ashley Walsh, Pocono Organics Founder/President. Formulated in-house, each Gourmet Gum Drop tin includes 25 servings and fits right in with Pocono Organics’ small batch, artisanal CBD product line featuring Bath Bombs, Nano-Particle Tincture, Hemp Extract Tincture, Creams, Salve Sticks, and Lip Balms. There’s even a pet-friendly Furry Friends Tincture! Learn more Pocono Organics CBD facts and focus on the future, including its water-soluble nano-particle technology, at PoconoOrganics.com/cbd. Pocono Organics – Inspiring People. Healing the Earth. 1015 Long Pond Road, Long Pond, PA – PoconoOrganics.com About Pocono Organics Pocono Organics is a health and wellness organization with a mission to inspire people and heal the earth. The Global Center for Research, Education, and Innovation grows the world’s first and only Regenerative Organic Certified (ROC) hemp and is one of the largest ROC farms in North America. Located in Long Pond, Pennsylvania, Pocono Organics has more than 380 acres of farmland and, at full build out, will have 120,000 square feet of greenhouse. Pocono Organics has a strategic partnership with Rodale Institute, the global leaders in Regenerative Organic Agriculture science and research and is their largest research satellite facility. Awarded the 2019 Environmental Innovator of the Year by the Green Sports Alliance, sustainability is a hallmark of Pocono Organics. The farm draws power from a 3MW, 25-acre solar farm and reclaims rainwater from 70,000 square feet of roofs for irrigation. Pocono Organics also serves the local community through its Clean Food, Dirty Hands school education program and veterans in transition through a Veteran Farmer Training Program. In addition, the property includes an organic farmer’s market and café featuring a Chopped Champion Chef, and with a 56-room adjoining hotel, is an agritourism destination, and host location for annual festivals. Please visit www.PoconoOrganics.com to learn more about Pocono Organics’ mission and work. Contact Details Pocono Organics Jeanine Hofbauer, Corporate Director of Marketing & Communications +1 570-517-1792 Jeanine@PoconoOrganics.com Company Website https://www.poconoorganics.com/

November 15, 2021 02:00 PM Eastern Standard Time

Image

EXCHANGE LISTING, LLC ADVISES HEARTBEAM INC. AND SECURES NASDAQ LISTING

Exchange Listing

Exchange Listing, LLC has finalized the Nasdaq Capital Markets listing for its client, Heartbeam Inc. (“ HeartBeam ” or the “Company”) (Nasdaq: BEAT and BEATW) on November 11 2021. The emerging digital healthcare company’s common stock began trading on the Nasdaq exchange under the symbols BEAT and BEATW, respectively. Concurrent with the NASDAQ listing, HeartBeam announced the pricing of its underwritten initial public offering of 2,750,000 units, each consisting of (i) one share of common stock and (ii) one warrant to purchase a share of common stock, at a public offering price per unit of $6.00 The warrants have an exercise price of $6.00 per share and are exercisable for a period of five years after the issuance date. All units are being offered by HeartBeam, Inc. In addition, HeartBeam has granted the underwriters a 30-day option to purchase an additional 412,500 shares of its common stock and/or warrants to purchase up to an additional 412,500 of its common stock, at the initial public offering price, less the underwriting discounts and commissions. The gross proceeds to HeartBeam from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $16.5 million. The Benchmark Company acted as the sole book-running managers for the offering. The Company, based in Santa Clara, California is a developmental stage digital healthcare company with a proprietary ECG telemedicine technology to bring new capabilities to cardiovascular disease, “Working with Exchange Listing as IPO counsel put us in a winning position,” commented Branislav Vajdic, CEO, HeartBeam. “Their exemplary team put us in contact with a best in class investment banker and legal team. We are thrilled to now be listed on the Nasdaq Capital Markets.” “When we met the HeartBeam management team, and reviewed their innovative digital healthcare products, we became incredibly enthusiastic about their market potential,” explains Peter Goldstein, Chief Executive Officer of Exchange Listing. “ HeartBeam’s medical grade heart attack detection technology is a game changer, allowing patients to determine if they are having a life threatening medical event. In concert with HeartBeam’s management and bankers, the Company now has a listing on Nasdaq Capital Markets.” Exchange Listing provides companies with cost-effective and efficient direct access to one-stop solutions in the strategic planning and implementation of listing and uplisting on senior exchanges such as the Nasdaq or NYSE. Focusing on company-specific structuring to meet listing requirements, Exchange Listing serves as the primary point of contact with the exchange, investment bankers and lawyers throughout the listing process. With extensive experience in investment banking, securities law, corporate governance and business management, Exchange Listing and its strategic partners facilitate clients' listing and capital markets objectives. About Exchange Listing Exchange Listing provides growth companies with direct access to a one-stop solution in the strategic planning and implementation of listing on a senior exchange such as NASDAQ or NYSE in a cost effective and efficient process. We assist clients in going public whether through an initial public offering, listing from another marketplace, merger or direct offering. We serve as the primary point of contact with the exchange, investment bankers, lawyers and other service providers. Our founders, strategic partners and advisors are entrepreneurs with backgrounds in investment banking, securities law, corporate governance and business management and have served as officers and directors of public and private companies. We pride ourselves in taking a hands-on role with our clients throughout the listing process. For more information, please visit: www.exchangelistingllc.com or contact info@exchangelistingllc.com. Contact Details Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://exchangelistingllc.com/

November 15, 2021 01:17 PM Eastern Standard Time

Doseology Set to Trade CSE: MOOD

Doseology Sciences Inc.

Doseology Sciences Inc. (CSE: MOOD ) (“ Doseology ” or the “ Company ”) is pleased to announce that its shares will begin trading on the CSE today and has retained Hybrid Financial Ltd. (“ Hybrid ”) to provide marketing and call centre services to the Company. Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange (the “ CSE ”) in providing their services. Hybrid has been engaged by the Company for an initial period of six (6) months starting from November 15, 2021 (the “ Initial Term ”) and shall be renewed for an additional six (6) months thereafter, unless terminated by the Company in accordance with the Agreement. Hybrid will be paid a monthly fee of $22,500 plus applicable taxes, during the Initial Term. Daniel Vice, CEO and Director commented, “We look forward to Hybrid amplifying market awareness to the Doseology brand and broadening the Company’s reach within the investment community”. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director About Doseology Sciences Inc. Doseology is a British Columbia-based diversified life sciences company, on a mission to reimagine mental health therapies through innovation, technology and sustainability. With a focus on psychedelic and non-psychedelic compounds, Doseology will offer cutting edge therapeutic products and services, with the aim of making a meaningful impact on the mental health pandemic and improving overall health. About Hybrid Financial Ltd. Hybrid is a sales and distribution company that actively connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets, Hybrid Financial offices in Toronto, and Montreal. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 15, 2021 08:00 AM Eastern Standard Time

Customer Experience and Customer Engagement Market to Surpass $100 Billion in Annual Worldwide Revenue by 2026, According to Dash Research

Dash Network

Customer experience (CX) and customer engagement (CE) initiatives continue to be a major priority for organizations around the world, especially in light of the significant changes and disruptions to customer relationships that emerged as a result of the COVID-19 pandemic. According to a new report from Dash Research, this level of focus is leading to brisk growth in the market for CX/CE technology platforms. “While CX improvements are largely driven by organizational change management, software is increasingly being used to support these initiatives by managing and making available the plethora of customer data that is captured and aggregated from a variety of sources,” says principal analyst Keith Kirkpatrick. He adds that some of the key drivers of market growth include pandemic-related shutdowns and reopening, increased focus on omnichannel customer interaction capabilities, the rise of customer centricity, and the elimination of functional silos within organizations. Dash Research forecasts that global CX/CE revenue will increase from $63.6 billion in 2021 to $100.3 billion by 2026. The market size experienced a 13.5% decline between 2019 and 2020 due to economic effects of the COVID-19 pandemic, but spending has recovered in 2021 and is projected to reach 2019 levels again by the end of 2022. The market intelligence firm forecasts that the top 5 industries in terms of CX/CE spending between 2021 and 2026 will be as follows: Telecommunications Healthcare Financial Services & Insurance Retail Government/Public Sector Dash Research’s report, “CX Market Forecasts”, includes a detailed market sizing and forecast model that focuses on the business-to-business (B2B) and business-to-consumer (B2C) software and services opportunity related to CX and CE. The forecast is split into a variety of segments, based on the world region in which the solution is used, the offering itself, functional area, and industry. The impact of the COVID-19 pandemic, the market drivers and barriers, and insights into four industries that are driving the market spending are discussed in the report, along with recommendations for both end users and vendors. An Executive Summary of the report is available for free download on the firm’s website. Dash Research, the market intelligence arm of Dash Network, provides in-depth research and insights on the worldwide CX market including a comprehensive assessment of technology solutions, business issues, market drivers, and end-user dynamics across industry sectors. Dash Research’s global market coverage combines qualitative and quantitative research methodologies to provide a complete view of emerging business opportunities surrounding contact center technologies, customer data & analytics, customer data platforms, customer insights & feedback, customer relationship management, personalization & optimization, and employee experience. For more information, visit www.dashresearch.com or call +1.720.603.1700. Contact Details Clint Wheelock +1 720-603-1700 press@dashnetwork.com Company Website http://www.dashnetwork.com

November 15, 2021 05:30 AM Eastern Standard Time

Doseology Receives Receipt for Final Prospectus and Announces Listing on the CSE

Doseology Sciences Inc.

NOT FOR DISTRIBUTION IN THE UNITED STATES OR DISSEMINATION IN THE UNITED STATES Doseology Sciences Inc. (“ Doseology ” or the “ Company ”), a diversified life sciences company, is pleased to announce that it has obtained a receipt for its final non-offering, long form prospectus dated October 29, 2021 from the British Columbia Securities Commission. Concurrent with its prospectus filing, the Company also received approval from the Canadian Securities Exchange (the “ CSE ”) to list the Company’s common shares on the CSE. The approval results in the Company’s previously issued 11,885,000 Subscription Receipts (aggregate gross proceeds of $2,377,000) to be automatically converted, without further payment, into 5,942,500 units. Each unit is comprised of one common share (a “ Share ”) and one common share purchase warrant (a “ Warrant ”) with each Warrant exercisable into one Share at a price of $0.80 per Share for a period of 24 months. The Company may elect, at its option, to accelerate the expiry date of the Warrants to a date that is 30 days from the date of notice to the Warrant holders if the closing price of the Shares on the CSE is equal to or greater than $1.40 for 20 consecutive trading days. The common shares of the Company will commence trading on the CSE on Monday, November 15, 2021 under the symbol “ MOOD ”. Daniel Vice, CEO of Doseology, commented “We are thrilled to finally obtain our listing on the CSE and are appreciative of the significant efforts of our team, our advisors, and the exchange to get to the finish line”. Mr. Vice further commented, “We now look forward to significantly accelerate the development of our ambitious business plan, through organic growth, partnerships, joint ventures and acquisitions“. No securities regulatory authority has either approved or disapproved of the contents of this news release. The units have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Accordingly, the Units may not be offered or sold within the United States or to U.S. persons (as defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws, or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of Doseology in any jurisdiction in which such offer, solicitation or sale would be unlawful. On Behalf of the Board of Directors Doseology Sciences Inc. Daniel Vice Chief Executive Officer and Director ABOUT DOSEOLOGY (CSE: MOOD) Doseology is a BC-based company on a mission to restore mental health through establishing psychedelic-assisted therapy clinics, building a library of intellectual property through research on psychedelic compounds, and the development and sale of its branded functional mushroom products. The Company has filed an application with Health Canada to become a “Licensed Dealer” under the Controlled Drugs and Substances Act (Canada) which would permit the laboratory analysis of psilocybin and psilocin from mushrooms, as well as the possession, processing, sale, sending, transportation and delivery of Psychedelic Compounds. FOR FURTHER INFORMATION CONTACT: Investor Relations Email: investor@doseology.com Telephone: 236-349-0064 Website: www.doseology.com Forward Looking Statements This press release contains statements which constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information except as otherwise required by applicable law. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. Contact Details Investor Relations +1 236-349-0064 investor@doseology.com

November 12, 2021 06:21 PM Eastern Standard Time

iHealth to Demo New COVID-19 In-Home Rapid Test

ShowStoppers and Keiretsu Forum Southern California

iHealth will introduce and demo its new in-home COVID-19 Antigen Rapid Test, with results in 15 minutes, just authorized by the FDA under an Emergency Use Authorization, to journalists attending a live stream of ShowStoppers TV ( https://www.showstoppers.com ) scheduled for today, Friday, 12 Nov. 2021. Journalists and potential investors will also discover 12 startups with healthtech tools, cannabis platforms, fuels that reduce pollution, tech to make lithium batteries safer, and more -- companies mentored by Keiretsu Forum Southern California ( https://www.k4Socal.com ). The press conference streams live, online, beginning today at Noon Eastern, continuing to 330 pm Eastern. To register to attend, journalists may contact Steve Leon, partner, ShowStoppers, sl@showstoppers.com. This is the first joint event organized by ShowStoppers and Keiretsu Socal. ShowStoppers ® announced in late October it is partnering with Keiretsu SoCal to help journalists discover startups mentored and funded by the community of accredited private-equity and angel investors, venture capitalists, corporate and institutional investors, incubators, business leaders, entrepreneurs and universities. Keiretsu SoCal is a region within Keiretsu Forum, a worldwide network of 3,000 investors organized into 60 chapters on 3 continents with capital, technology, talent, resources and deal flow that to date has invested more than $1B USD into companies – including a record 314 fundings into seed, early-stage and late-stage companies during 2020, led by life science, healthcare and medical devices, consumer products, and environmental and emerging technologies. The Southern California region of Keiretsu Forum comprises four chapters in San Diego, Westlake Village, Los Angeles and Orange County. The presenting startups include: BOMANI, maker of Cold Buzz, an award-winning alcohol-infused cold brew coffee that has earned shelf space at Ralph’s, Whole Foods, Total Wine, Stater Bros. Crafty Elk ® -- named the world’s first ‘Smart Alcohol’ by the Huffington Post. smallTalk™ -- a consumer technology startup that just launched the smallTalk Egg, the first in a line of IoT products that enable parents to introduce children to foreign languages through play, starting in infancy and preschool. Soteria -- enabling a world where lithium-ion batteries and the devices they power are inherently safe. Supported by an open-innovation consortium with over 100 active partners, including NASA, Mercedes-Benz, Motorola, Lenovo, Bosch, DuPont, Applied Materials. StressFree TC -- processing 4-5 times more real estate files than a human, saving agents and brokers thousands of dollars and hundreds of hours of time. Genetica -- leveraging machine learning, natural language processing, AI and data science to build a cannabis platform that identifies the provenance and efficacy of what is grown, bought, sold and consumed. Trillion -- entering the sea-trial stage with one of the largest cruise line corporations of ESG fuels (Environmental, Social and Governance) that are up to 90% more effective in reducing engine pollution, and 15% more fuel efficient. Perfect Point EDM -- designing solutions for Aerospace's most-overlooked problems. InControl Medical -- designs and manufactures patented devices for the control of incontinence. Inhalio -- agreements with Philips/Lumileds and Acqua Di Parma to license and integrate the Digital Scent 3.0 Platform in the IoT Automotive and Home markets. Inmedix -- an innovative cloud platform that predicted rheumatoid arthritis (RA) treatment outcome a year in advance and guided increased RA remission from 25% to 79%. Orion Biotechnology -- a proprietary drug discovery platform to grow a pipeline of high value drug candidates and unlock therapeutics. “Entrepreneurs need more than funding,” said Connie Harrell, Regional President, Keiretsu Forum So Cal. “They also need exposure with the press, marketing and promotions, to create a generous return for the investors who mentor and fund those entrepreneurs – which begins with this press conference, streaming online, live, powered by ShowStoppers.” About ShowStoppers Now in its 26th year, ShowStoppers, https://www.showstoppers.com, is the global leader in producing press and business events spanning the U.S., Europe and Asia. Each event organizes product launches, sneak previews and demonstrations for selected journalists, bloggers, industry and financial analysts, venture capitalists and business executives. Industry leaders, innovators and startups exhibit to generate news coverage and product reviews, make new connections, promote brand and open new markets. ShowStoppers produces official press events at CE Week, IFA and NAB; partners with CTA, IFA, GSMA and CEATEC; and produces events during CES, IFA, MWC, NAB, CE Week, CEATEC and other tradeshows. ShowStoppers streams online, broadcasting live events, month after month. To learn more about how you and your company can meet the press at ShowStoppers press events in person and online at ShowStoppers TV, contact Lauren Merel, lauren@showstoppers.com, +1 908-692-6068, or Dave Leon, dave@showstoppers.com, +1 845-821-6123. Contact Details For press registration, please contact Steve Leon +1 310-936-8530 sl@showstoppers.com For Keiretsu Forum Southern California, please contact Cindy Fraley +1 949-899-4849 hello@k4socal.com

November 12, 2021 09:00 AM Eastern Standard Time

Healthcare Industry’s First Carbon Tech Platform Launched by Zasti

Zasti

Zasti, an advanced analytics enterprise that offers carbon tech solutions and strong environmental, social, and governance (ESG) values to the United States healthcare marketplace, announced it is collaborating with Change Healthcare (NASDAQ: CHNG), a health care technology leader. The two companies are aiming to build efficiencies and reduce carbon emissions generated by the healthcare industry. Combining billions of data points from Change Healthcare with Zasti’s AI technology allows users to Assess, Target, Optimize, and Monitor ( ATOM TM ) carbon emissions. “Working with Change Healthcare to deploy ATOM throughout the healthcare industry will allow organizations to be more efficient as decarbonization strategies are considered and implemented” explained Krish R. Krishnan, Zasti’s CEO. “The healthcare industry is responsible for a tenth of all greenhouse gas emissions, making it a focal point for stakeholder scrutiny”. Zasti’s ATOM provides precise measurement of direct and indirect carbon emissions via a proprietary healthcare carbon database. With this data, carbon emission hotspots are identified using pre-designed algorithms providing uses with an AI-driven decarbonization strategy. “The power of our collaboration is combining real-world data that is already processed by Change Healthcare with Zasti’s ATOM platform,” said Tim Suther, senior vice president and general manager of Data Solutions at Change Healthcare. “A provider’s carbon baseline can be quickly established with visibility into how individual procedures and activities contribute to carbon emissions. The ATOM platform then provides benchmarks and actionable insights to reduce those emissions. Real-time data-driven actions can then facilitate carbon emission reductions.” Zasti’s ATOM AI technology offers solutions that achieve continuous optimization and offsetting of carbon emissions. It also tracks the real-time progress of emission reductions through a user-friendly dashboard that integrates with accounting, sustainability, and disclosure details. Dr. David Chang, leading cataract surgeon at the Peninsula Eye Surgery Center in Northern California shared his perspective by stating, “The carbon footprint of the healthcare sector in general, and the operating room in particular, is surprisingly large. We have an important opportunity to make an impact by being more green and by reducing needless OR waste.” “Like all industries today, healthcare too must accelerate the decarbonization process. No industry, especially healthcare, is immune from the responsibility to strive for achieving net-zero emissions. Nor can an industry dodge the looming regulations imposing a plan and the actions moving toward net-zero emissions”, Krishnan, also a Delegate to COP26, stated. “Our collaboration with Change Healthcare is a major step in revolutionizing the healthcare industry by making it sustainable.” About Zasti The Zasti proprietary carbon emission metrics database and AI platform offer a granular, accurate baselining of emission and configurable ESG (Environmental, Social, & Governance) compliance reports. The Zasti AI analytics suite provides management teams with fact-based, real-time, actionable insights that deliver meaningful progress toward meeting decarbonization goals. To automate your decarbonization goals, visit https://www.zasti.ai/ ### For more information or to schedule an interview with Krish Krishnan, contact Dan Rene at 202-329-8357 or daniel.rene@kglobal.com. Contact Details kglobal Dan Rene +1 202-329-8357 daniel.rene@kglobal.com Company Website https://zasti.ai/

November 11, 2021 10:00 AM Eastern Standard Time

BIOSAPIEN CLOSES $1.8M SEED ROUND LED BY SOSV & HIKMA VENTURES

Biosapien

BioSapien, a biotech company has announced it has raised $1.8M in seed round funding led by global venture capital investor SOSV. Co-investors in the round include Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high-net worth angels and investors (Additional investors listed below*). In addition to the seed round funding, a non-dilutive grant of $256K from the National Science Foundation will accelerate the development of BioSapien’s patented product, MediChip ™: a 3D printed biodegradable mesh chip designed to deliver cancer drugs directly to the tumor site while reducing side effects. “It’s great to have the support of these esteemed investors in BioSapien,” says Dr. Khatija Ali, CEO and co-founder of BioSapien. “The seed round funds will advance development of MediChip ™ and give access to global distribution channels and manufacturing. Chemotherapy can cause devastating side effects for patients. MediChip ™ is designed to deliver cancer drugs straight to hard-to-reach tumor sites, for increased efficacy with reduced toxicity.” MediChip ™ is a novel biodegradable drug delivery platform designed to precisely administer any type of FDA-approved drug, locally and in a sustained manner. Pre-clinical research shows that in comparison to systemic chemotherapy, MediChip ™ mitigates systemic side-effects through localized controlled release. For cancer indications, it has the potential to improve the patient’s quality of care and life. It is designed to be a first-line treatment option for stage III locally advanced gastrointestinal cancer patients during surgery for adjuvant chemotherapy delivery. MediChip ™ was granted its patent in February 2021 with a priority date of December 21, 2018. Potential For Stage III, IV Pancreatic Cancer The current clinical pipeline includes BioSapien’s lead indication of pancreatic cancer and others including lung cancer, esophageal cancer, and colorectal cancer. There are approximately 57,000 new cases of pancreatic cancer in the US every year. Founded in 2018, in New York City, NY, BioSapien has already garnered global attention. In addition to the seed round funding and NSF grant which Inspiralia assisted in securing, BioSapien has been recognized in high profile biotech pitch competitions, winning the Pitch Night by Amazon and the Get in the Ring Start Up Competition. The company is currently a semi-finalist in the PacBio 2021 conference. Now, with backing from SOSV, Hikma, and JPIN VCATS, MediChip ™ has strategic partners, financial backing, and global reach to progress towards achieving the goal of impacting patient care worldwide. * Additional investors include; SOSV, Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, Harbr, Beni VC, Cedas Foundation, Kartik Garg - The Modern Nomad, George and Saul, and other angels About BioSapien BioSapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company invented MediChip ™: a patented treatment that early research has shown can reduce the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh is designed to allow for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects. For more information, visit www.biosapien.com. About SOSV SOSV is a global venture capital firm headquartered in Princeton, NJ. The firm has more $900 million in assets under management and more than 1,000 portfolio companies. SOSV operates the startup development programs HAX (hard tech), IndieBio (life sciences), Chinaccelerator and MOX (cross-border growth in Asia) and dlab (blockchain). Sean O'Sullivan, a serial entrepreneur and technologist, is the founder of SOSV. The firm has 8 general partners and a 130-person staff across seven locations in the US, Europe and Asia. About Hikma Hikma helps put better health within reach every day for millions of people around the world. For more than 40 years, Hikma has been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, Hikma is a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and uses their unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. Hikma is committed to their customers, and the people they care for, and by thinking creatively and acting practically, Hikma provides them with a broad range of branded and non-branded generic medicines. Together, Hikma’s 8,600 colleagues are helping to shape a healthier world that enriches everyone’s communities. Hikma is a leading licensing partner, and through their venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com. About Hikma Ventures Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals. Hikma Ventures invests in global start-ups where Hikma's expertise can accelerate revenue growth and enhance value creation by providing ventures with access to the resources of a multinational pharmaceutical company. For more information, please visit www.hikmaventures.com. About Biosapien Biosapien Inc. is a venture-backed biotechnology company focused on innovative therapies to transform patient care. The company developed MediChip ®: a patented treatment that reduces the system-wide side effects of cancer chemotherapy treatments. The 3D printed biodegradable mesh allows for a more exact delivery of already approved FDA pharmaceuticals without the adverse effects Contact Details WantLeverage Communications Julie Livingston +1 347-239-0249 julie@wantleverage.com Company Website https://biosapien.com/

November 11, 2021 08:03 AM Eastern Standard Time

1 ... 243 244 245 246 247 ... 301